Nutritional Approach to Metabolic Changes Arising Out of Schizophrenia Therapy: Case Report

Özenoğlu, Aliye; Uğurlu, Serdal; Balcı, Huriye; Eker, Engin

doi:10.2169/internalmedicine.46.6323

Cited by 9 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We hope that the results obtained will elucidate the way for the later studies made in this area for different diseases, different treatments or different regions in this area. As a matter of fact, the results of this study which were performed in a large group, could be also beneficial and helpful for the other studies we made so far (Ozenoglu et al 2000(Ozenoglu et al , 2001a(Ozenoglu et al ,b, 2004(Ozenoglu et al a,b, 2006(Ozenoglu et al , 2007a. We suggest to use the results of this study as reference values in similar studies, and also we choose to share this study by publishing to be a countenance for the investigators curious about the changes in the body composition for different conditions, different groups, different diseases and treatments in several countries.…”

mentioning

confidence: 56%

Reference Values of Body Composition for Adult Females Who Are Classified as Normal Weight, Overweight or Obese According to Body Mass Index

Özenoğlu

Uğurlu²,

Can³

et al. 2009

endo

View full text Add to dashboard Cite

The aim of this study was to establish reference values for body composition as measured by Bioelectrical Impedance Analyser (BIA) in adult females without any endocrinological and/or metabolic disorders, according to their body mass index (BMI) grouped as normal, overweight, obese and morbid obese. Patients and Methods. This study was performed in a total of 327 adult females. In addition to the estimation of their body weight, height, waist and hip circumference, their body composition was measured by BIA. The results were statistically evaluated by a computer program usig ANO-VA test. Results. Together with the increase of BMI also the percentage of body fat and basal metabolism (BM) increased significantly, while the percentage of body water, fat free mass as well as lean/ fat ratio showed a significant decrease. In addition, waist and hip ratio, percentage of body fat and BM showed a significant positive corelation with BMI. Conclusion. These results are recommended to be used as reference values for the studies on body composition, especially to predict the degree of body fatness of obese patients and also nutritional status of patients who need nutritional supports.

show abstract

mentioning

confidence: 56%

Reference Values of Body Composition for Adult Females Who Are Classified as Normal Weight, Overweight or Obese According to Body Mass Index

Özenoğlu

Uğurlu²,

Can³

et al. 2009

endo

View full text Add to dashboard Cite

show abstract

“…The authors of the Cochrane review conclude that their findings in 2008 are concurrent with those of the 2005 systematic review, with both agreeing that larger, longer trials are needed (24,25). In due course, CVD outcomes will be needed to assess any longer‐term benefits of metformin (55–61).…”

Section: Discussionmentioning

confidence: 99%

Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies

Bushe¹,

Bradley²,

Doshi³

et al. 2009

International Journal of Clinical Practice

View full text Add to dashboard Cite

Summary Background: Changes in weight and metabolic parameters have been commonly reported in patients with schizophrenia. Metformin has been evaluated in clinical studies to prevent or reduce weight gain and changes in metabolic parameters in non‐diabetic subjects. We undertook a systematic review of the efficacy and safety of metformin in reducing weight gain and metabolic abnormalities in non‐diabetic subjects with schizophrenia or bipolar disorder taking antipsychotic medication to establish if these data could potentially drive guideline development. Methods: Medical databases were searched using terms including ‘antipsychotic’, ‘atypical antipsychotic agent’, ‘antipsychotic agents’, ‘antipsychotic‐drug’ and ‘metformin’ and ‘weight’. Studies reporting weight and/or metabolic outcomes in non‐diabetic subjects with schizophrenia and bipolar disorder were included regardless of methodological type and subject age. Results: Nine randomised double‐blind studies and two open cohort studies evaluating metformin and changes in weight in trials up to 16 weeks were identified. In all, 495 participants received antipsychotics (mostly olanzapine), and three studies were in subjects aged < 18 years. The adult studies predominantly utilised non‐Caucasian subjects with chronic schizophrenia. Weight and lifestyle intervention programmes were provided to all cohorts in eight studies, which confounded interpretation of the data. In ten studies, the addition of metformin to antipsychotic treatment was associated with either significantly attenuated weight gain or weight loss compared with control groups. Nine studies measured various glucose parameters. In four studies, subjects prescribed metformin had significantly improved glucose parameters relative to controls. The two studies of metformin in patients with first‐episode schizophrenia demonstrated the largest improvement in weight and glucose parameters. Conclusions: Metformin may have some value in reducing or preventing weight gain and changes in metabolic parameters during treatment with antipsychotic medication particularly in first‐episode psychosis; however, it has been predominantly studied short‐term and in non‐Caucasian populations. A number of new trials are due to report data 2009–2013 to aid definitive interpretation of the role of metformin. Further longer‐term studies are warranted before definitive guidelines can be established.

show abstract

“…Bu nedenle, henüz ilaçla tedavi gelişmeden önce epilepsi tedavisinde yüksek yağlı, ketozisi ilerleten bir diyet uygulanmıştır. 6 Fransız doktorlardan Guelpa ve Marie 1911 yılında, 20 hastayı 4 gün aç bırakarak nöbet kontrolünde bazı iyileşmeleri gözlemlemiş ve epilepside "Çok iyi beslenme"nin gerekliliğini vurgulayarak modern literatürde bir ilk olmuşlardır. Dr. Geyelin, 1921 yılında, "Bromit ve fenobarbital"ler ile epilepsinin kontrol altına alınamadığını rapor etmiş ve aynı yıl Mayo Klinik'te açlığın biyokimyasal etkilerini taklit etmek için yüksek yağ ve düşük karbonhidrat içeren diyet Dr. Wilder tarafından dirençli epilepsisi olan çocuklara uygulanmıştır.…”

Section: Di̇yet Tedavi̇si̇ni̇n Tari̇hçesi̇unclassified

“…Fakat 1938 yılında difenilhidantoin gibi yeni ilaçların kullanılmaya başlanmasıyla, diyet tedavisi doktorlar tarafından zor, kuralcı ve pahalı bulunmaya başlanmış ve popülaritesini yitirmiştir. 6 Zeynep CAFEROĞLU Turkiye Klinikleri J Health Sci. 2019;4(3):333-47 "Charlie Foundation" adlı derneğin 1994 yılında kurulmasıyla, diyet tedavisine olan ilgi Amerika Birleşik Devletleri'nde yeniden canlanmış ve 3-4 yıl içerisinde tüm dünyaya yayılmıştır.…”

Section: Di̇yet Tedavi̇si̇ni̇n Tari̇hçesi̇unclassified

Current Approaches to Diet Therapy in Epilepsy

Caferoğlu¹

2019

Turkiye Klinikleri J Health Sci

View full text Add to dashboard Cite

pilepsi Yunanca kökenli bir sözcük olup, "Tutmak", "Ansızın yakalanmak" anlamına gelmektedir ve antik çağlardan beri tanınan bir hastalıktır. Epileptik nöbetleri ve epilepsiyi tedavi etme deneyimleri, insanlığın ilk çağlarına kadar uzanır. Tarihin her devrinde epilepsinin nedeni ile ilgili yorumlara dayanılarak tedaviler uygulanmıştır. Önceleri bir Turkiye Klinikleri J Health Sci. 2019;4(3):333-47 333 Epilepside Diyet Tedavisine Güncel Yaklaşımlar Ö ÖZ ZE ET T Epilepsi, her yaştan insanı etkileyen kronik bir beyin hastalığıdır. Dünya genelinde yaklaşık 50 milyon insanın epilepsisi bulunmaktadır ve bu da epilepsiyi dünyadaki en yaygın nörolojik hastalıklardan biri yapmaktadır. Epilepsi tedavisinde hedef; nöbet sıklığını ve şiddetini azaltmak, mümkünse tam nöbet kontrolü sağlamak, tekrarlayan nöbetlerin oluşturacağı hasarları önlemek, hastanın günlük aktivitelerini yapabilmesini sağlamaktır. Çoğu nöbet bir veya daha fazla antiepileptik ilaç kullanılarak kontrol altına alınabilmektedir, ancak bir süre sonra bu ilaçlar nöbetler için yararlı olmayabilir ve bu durum, ilaca dirençli epilepsi olarak adlandırılmaktadır. Dirençli epilepsisi olan bireyler için özel diyet tedavileri düşünülebilir. Hipokrat zamanından günümüze epilepsi tedavisinde çeşitli diyetler kullanılmış olup, güncel literatürde kabul gören yaklaşım yüksek yağ ve düşük karbonhidrat içeriğine sahip olan ketojenik diyetlerdir. Ketojenik diyetlerin nöbet sıklığını azalttığı öne sürülmektedir. Farklı tipleri bulunan [klasik ketojenik diyet, orta zincir yağ asitleri (MCT) diyeti, modifiye MCT diyeti gibi] diyet tedavileri arasında, özellikle modifiye Atkins diyeti olmak üzere daha az kısıtlayıcı olan ketojenik diyetlere ilgi son zamanlarda artmıştır. Ayrıca, diyete omega-3 yağ asitlerinin eklenmesi, lizin kısıtlaması veya magnezyum desteği yapılması ve ketojenik parenteral nütrisyon gibi yeni diyet yaklaşımları ile ilgili araştırmalar da mevcuttur. Bu çalışmada, epilepsi tedavisinde kullanılan ketojenik diyet tipleri, nöbet kontrolündeki etkinlikleri, etki mekanizmaları ve olası yan etkileri ile diğer diyet tedavisi yaklaşımlarının açıklanması amaçlanmıştır.A An na ah h t ta ar r K Ke e l li i m me e l le er r: : İlaca dirençli epilepsi; ketojenik diyet; glisemik indeks; omega-3 yağ asitleri A AB BS S T TR RA AC CT T Epilepsy is a chronic brain disease that affects people of all ages. Approximately 50 million people worldwide have epilepsy, making it one of the most common neurological diseases in the world. The goal of the epilepsy treatment is to reduce the frequency and severity of the seizure, to ensure full seizure control if possible, to prevent the damage caused by recurrent seizures, to enable the patient to perform daily activities. Most seizures can be controlled using one or more anti-epileptic drugs, however after a while these drugs may not be useful for seizures, and this is called drug-resistant epilepsy. For individuals with resistant epilepsy, special dietary treatments may be considered. Various diets have been used in the epilepsy treatment...

show abstract

Nutritional Approach to Metabolic Changes Arising Out of Schizophrenia Therapy: Case Report

Abstract: The case of a 35-year-old

Cited by 9 publications

References 25 publications

Reference Values of Body Composition for Adult Females Who Are Classified as Normal Weight, Overweight or Obese According to Body Mass Index

Reference Values of Body Composition for Adult Females Who Are Classified as Normal Weight, Overweight or Obese According to Body Mass Index

Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies

Current Approaches to Diet Therapy in Epilepsy

Contact Info

Product

Resources

About